{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:28:28Z","timestamp":1772771308255,"version":"3.50.1"},"reference-count":52,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytotoxic T lymphocyte antigen 4 (CTLA4) is a major immune checkpoint and target for cancer immunotherapy. Although originally discovered and primarily studied on T cells, its role on other cell types has also been recognized in recent years. Here we describe an unexpected interaction between ibrutinib (a targeted inhibitor of Bruton tyrosine kinase [BTK]) and CTLA4 expression on malignant chronic lymphocytic leukemia (CLL) cells. Although BTK itself does play a role in CTLA4 expression in CLL, we demonstrate that ibrutinib\u2019s main suppressive effect on CTLA4 protein expression and trafficking occurs through non-BTK targets influenced by this drug. This suppression is not seen in T cells, indicating a different mechanism of CTLA4 regulation in CLL vs T cells. Appreciating this distinct mechanism and the beneficial non-BTK effects of ibrutinib may contribute to understanding the immune benefits of ibrutinib treatment and lead to therapeutic approaches to improve immune function in patients with CLL by suppressing CTLA4 expression.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005571","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T20:43:05Z","timestamp":1656362585000},"page":"5440-5448","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5845-0093","authenticated-orcid":false,"given":"Max","family":"Yano","sequence":"first","affiliation":[{"name":"1Medical Science Training Program, The Ohio State University College of Medicine, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Nunes","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, The Ohio State University (OSU), Cincinnati, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokui","family":"Mo","sequence":"additional","affiliation":[{"name":"3Center for Biostatistics, The Ohio State University College of Medicine Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, The Ohio State University (OSU), Cincinnati, OH;"},{"name":"4OSU Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, The Ohio State University (OSU), Cincinnati, OH;"},{"name":"4OSU Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, The Ohio State University (OSU), Cincinnati, OH;"},{"name":"4OSU Comprehensive Cancer Center, Columbus, OH; and"},{"name":"5Department of Internal Medicine, University of Cincinnati, Cincinnati, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-4504","authenticated-orcid":false,"given":"Natarajan","family":"Muthusamy","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, The Ohio State University (OSU), Cincinnati, OH;"},{"name":"4OSU Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"3","key":"2022092315285608700_B1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","author":"Williams","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"2022092315285608700_B2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol."},{"issue":"1","key":"2022092315285608700_B3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia."},{"issue":"5","key":"2022092315285608700_B4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2008.07050.x","article-title":"Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait","volume":"141","author":"Rossi","year":"2008","journal-title":"Br J Haematol."},{"issue":"4","key":"2022092315285608700_B5","first-page":"35","article-title":"Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia","volume":"9","author":"Dasanu","year":"2007","journal-title":"MedGenMed."},{"issue":"7","key":"2022092315285608700_B6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study","volume":"105","author":"Royle","year":"2011","journal-title":"Br J Cancer."},{"issue":"7","key":"2022092315285608700_B7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","article-title":"Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study","volume":"31","author":"Solomon","year":"2013","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022092315285608700_B8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","article-title":"Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study","volume":"30","author":"Brewer","year":"2012","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022092315285608700_B9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.leu.2403907","article-title":"Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia","volume":"19","author":"Motta","year":"2005","journal-title":"Leukemia."},{"issue":"9","key":"2022092315285608700_B10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood."},{"issue":"2","key":"2022092315285608700_B11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol Oncol Clin North Am."},{"issue":"15","key":"2022092315285608700_B12","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2022092315285608700_B13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.13467","article-title":"Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model","volume":"170","author":"Gassner","year":"2015","journal-title":"Br J Haematol."},{"issue":"1","key":"2022092315285608700_B14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2249.2001.01639.x","article-title":"Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL)","volume":"126","author":"Porakishvili","year":"2001","journal-title":"Clin Exp Immunol."},{"issue":"5","key":"2022092315285608700_B15","first-page":"1656","article-title":"Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines","volume":"9","author":"Gitelson","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2022092315285608700_B16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbmt.2008.10.022","article-title":"Stem cell transplantation in chronic lymphocytic leukemia","volume":"15","author":"Gribben","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022092315285608700_B17","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4049\/jimmunol.155.4.1776","article-title":"Activated T cells can induce high levels of CTLA-4 expression on B cells","volume":"155","author":"Kuiper","year":"1995","journal-title":"J Immunol."},{"issue":"1","key":"2022092315285608700_B18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.0300-9475.2001.01019.x","article-title":"Expression of CTLA-4 by human monocytes","volume":"55","author":"Wang","year":"2002","journal-title":"Scand J Immunol."},{"key":"2022092315285608700_B19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2172-12-21","article-title":"CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation","volume":"12","author":"Wang","year":"2011","journal-title":"BMC Immunol."},{"issue":"10","key":"2022092315285608700_B20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.humimm.2010.07.007","article-title":"CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions","volume":"71","author":"Laurent","year":"2010","journal-title":"Hum Immunol."},{"issue":"10","key":"2022092315285608700_B21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1089\/scd.2016.0009","article-title":"Dendritic cell-secreted cytotoxic T-lymphocyte-associated protein-4 regulates the T-cell response by downmodulating bystander surface B7","volume":"25","author":"Halpert","year":"2016","journal-title":"Stem Cells Dev."},{"issue":"4","key":"2022092315285608700_B22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.21155","article-title":"CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction","volume":"117","author":"Contardi","year":"2005","journal-title":"Int J Cancer."},{"issue":"18","key":"2022092315285608700_B23","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1158\/0008-5472.CAN-16-0342","article-title":"CTLA4 promotes Tyk2-STAT3\u2013dependent B-cell oncogenicity","volume":"77","author":"Herrmann","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"2022092315285608700_B24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2002-06-1668","article-title":"CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells","volume":"101","author":"Pistillo","year":"2003","journal-title":"Blood."},{"issue":"7","key":"2022092315285608700_B25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00262-015-1696-2","article-title":"Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis","volume":"64","author":"Yu","year":"2015","journal-title":"Cancer Immunol Immunother."},{"issue":"11","key":"2022092315285608700_B26","doi-asserted-by":"crossref","first-page":"13060","DOI":"10.18632\/oncotarget.7421","article-title":"Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget."},{"issue":"18","key":"2022092315285608700_B27","doi-asserted-by":"crossref","first-page":"26670","DOI":"10.18632\/oncotarget.8476","article-title":"Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget."},{"issue":"2","key":"2022092315285608700_B28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.leu.2403588","article-title":"CTLA-4 overexpression in CD19+\/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients","volume":"19","author":"Kosmaczewska","year":"2005","journal-title":"Leukemia."},{"issue":"9","key":"2022092315285608700_B29","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.4049\/jimmunol.1801359","article-title":"Leukemic B cell CTLA-4 suppresses costimulation of T cells","volume":"202","author":"Do","year":"2019","journal-title":"J Immunol."},{"issue":"19","key":"2022092315285608700_B30","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood."},{"issue":"8","key":"2022092315285608700_B31","doi-asserted-by":"crossref","first-page":"e70352","DOI":"10.1371\/journal.pone.0070352","article-title":"Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia","volume":"8","author":"Mittal","year":"2013","journal-title":"PLoS One."},{"issue":"3","key":"2022092315285608700_B32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10238-015-0360-7","article-title":"CTLA-4 affects expression of key cell cycle regulators of G0\/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia","volume":"16","author":"Ciszak","year":"2016","journal-title":"Clin Exp Med."},{"issue":"3","key":"2022092315285608700_B33","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s13277-015-4217-1","article-title":"Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody","volume":"37","author":"Ciszak","year":"2016","journal-title":"Tumour Biol."},{"issue":"2","key":"2022092315285608700_B34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood."},{"issue":"26","key":"2022092315285608700_B35","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2022092315285608700_B36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med."},{"issue":"8","key":"2022092315285608700_B37","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest."},{"issue":"21","key":"2022092315285608700_B38","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood."},{"issue":"15","key":"2022092315285608700_B39","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2022092315285608700_B40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem."},{"issue":"11","key":"2022092315285608700_B41","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y","article-title":"A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells","volume":"29","author":"Magistrelli","year":"1999","journal-title":"Eur J Immunol."},{"issue":"2","key":"2022092315285608700_B42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/cimm.2000.1649","article-title":"A native soluble form of CTLA-4","volume":"201","author":"Oaks","year":"2000","journal-title":"Cell Immunol."},{"issue":"2","key":"2022092315285608700_B43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","article-title":"The soluble CTLA-4 receptor and its role in autoimmune diseases: an update","volume":"1","author":"Saverino","year":"2010","journal-title":"Auto Immun Highlights."},{"issue":"9","key":"2022092315285608700_B44","doi-asserted-by":"crossref","first-page":"e44654","DOI":"10.1371\/journal.pone.0044654","article-title":"A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression","volume":"7","author":"Simone","year":"2012","journal-title":"PLoS One."},{"issue":"8","key":"2022092315285608700_B45","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.31557\/APJCP.2020.21.8.2225","article-title":"Prognostic value of CD200 expression and soluble CTLA-4 concentrations in intermediate and high-risk myelodysplastic syndrome patients","volume":"21","author":"Aref","year":"2020","journal-title":"Asian Pac J Cancer Prev."},{"issue":"3","key":"2022092315285608700_B46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2249.2007.03513.x","article-title":"Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y","volume":"150","author":"Huurman","year":"2007","journal-title":"Clin Exp Immunol."},{"issue":"5","key":"2022092315285608700_B47","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/eji.201242529","article-title":"The soluble isoform of CTLA-4 as a regulator of T-cell responses","volume":"43","author":"Ward","year":"2013","journal-title":"Eur J Immunol."},{"issue":"9","key":"2022092315285608700_B48","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov."},{"issue":"2","key":"2022092315285608700_B49","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/bbrc.1998.9191","article-title":"Src family tyrosine kinases associate with and phosphorylate CTLA-4 (CD152)","volume":"249","author":"Miyatake","year":"1998","journal-title":"Biochem Biophys Res Commun."},{"issue":"2","key":"2022092315285608700_B50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/(SICI)1097-4644(20000801)78:2<241::AID-JCB7>3.0.CO;2-K","article-title":"Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4","volume":"78","author":"Chikuma","year":"2000","journal-title":"J Cell Biochem."},{"issue":"8","key":"2022092315285608700_B51","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"2022092315285608700_B52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3389\/fimmu.2014.00619","article-title":"Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4","volume":"5","author":"Schneider","year":"2014","journal-title":"Front Immunol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5440\/1922212\/advancesadv2021005571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5440\/1922212\/advancesadv2021005571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T20:20:00Z","timestamp":1675974000000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/18\/5440\/485701\/Differential-regulation-of-CTLA4-expression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":52,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,9,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005571","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}